Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
Abstract Background Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selecti...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMC
2022-07-01
|
| Sarja: | Microbial Cell Factories |
| Aiheet: | |
| Linkit: | https://doi.org/10.1186/s12934-022-01873-7 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|